Catalyst Pharma (CPRX) Stock Rating Reaffirmed by Analysts at Roth Capital; The $4.75 Target Indicates 71.48% Potential; 8 Analysts Covering Express Scripts Holding Company (ESRX)

August 31, 2017 - By Ellis Scott

Among 20 analysts covering Express Scripts (NASDAQ:ESRX), 8 have Buy rating, 3 Sell and 9 Hold. Therefore 40% are positive. Express Scripts had 34 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Express Scripts Holding Company (NASDAQ:ESRX) has “Neutral” rating given on Tuesday, June 7 by Bank of America. The firm earned “Hold” rating on Wednesday, July 26 by Oppenheimer. The rating was maintained by Barclays Capital with “Overweight” on Thursday, February 18. Maxim Group maintained the shares of ESRX in report on Wednesday, July 26 with “Buy” rating. The firm has “Market Perform” rating given on Tuesday, January 19 by Leerink Swann. Morgan Stanley maintained Express Scripts Holding Company (NASDAQ:ESRX) on Thursday, August 10 with “Underweight” rating. The stock of Express Scripts Holding Company (NASDAQ:ESRX) earned “Neutral” rating by UBS on Thursday, October 6. The firm has “Outperform” rating by Credit Suisse given on Tuesday, April 26. The rating was maintained by Leerink Swann with “Outperform” on Monday, October 5. The firm has “Sell” rating given on Monday, February 22 by Deutsche Bank. See Express Scripts Holding Company (NASDAQ:ESRX) latest ratings:

29/08/2017 Broker: Jefferies Rating: Buy New Target: $72.0 Maintain
10/08/2017 Broker: Morgan Stanley Rating: Underweight Old Target: $52 New Target: $57 Maintain
26/07/2017 Broker: Maxim Group Rating: Buy New Target: $78.0000 Maintain
26/07/2017 Broker: Oppenheimer Rating: Hold Maintain
21/07/2017 Broker: Needham Rating: Hold Initiates Coverage On
18/07/2017 Broker: Maxim Group Rating: Buy New Target: $78.0000 Maintain
07/07/2017 Broker: Jefferies Rating: Buy New Target: $67.0000 Maintain
08/06/2017 Broker: Cowen & Co Rating: Buy Maintain
01/06/2017 Broker: Credit Suisse Rating: Buy New Target: $85.0000 Maintain
26/05/2017 Broker: Jefferies Rating: Buy New Target: $67.0000 Maintain

Among 4 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $600 highest and $4 lowest target. $5.19’s average target is 87.36% above currents $2.77 stock price. Catalyst Pharmaceuticals had 6 analyst reports since April 26, 2016 according to SRatingsIntel. The firm has “Buy” rating by Roth Capital given on Thursday, August 10. As per Tuesday, April 26, the company rating was downgraded by Piper Jaffray. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) earned “Overweight” rating by Piper Jaffray on Wednesday, October 5. The company was maintained on Friday, August 11 by H.C. Wainwright. The stock of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) earned “Buy” rating by Piper Jaffray on Monday, August 7. PiperJaffray upgraded Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) rating on Wednesday, October 5. PiperJaffray has “Overweight” rating and $4 target.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The company has market cap of $234.22 million. The Firm is focused on developing and commercializing therapies for people with rare debilitating diseases. It currently has negative earnings. The Firm has three drugs in development: Firdapse, CPP-109 and CPP-115.

It closed at $2.77 lastly. It is down 267.48% since August 31, 2016 and is uptrending. It has outperformed by 250.78% the S&P500.

Investors sentiment increased to 2.22 in 2016 Q4. Its up 1.01, from 1.21 in 2016Q3. It improved, as 6 investors sold Catalyst Pharmaceuticals Inc shares while 12 reduced holdings. 9 funds opened positions while 8 raised stakes. 23.81 million shares or 1.65% more from 23.42 million shares in 2016Q3 were reported. Cwm Ltd Llc invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Commonwealth Equity Services, Massachusetts-based fund reported 24,000 shares. Blackrock Fund Advsr invested 0% of its portfolio in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Provise Mngmt Gp Limited Liability Corp invested in 0% or 19,000 shares. Millennium Ltd Liability Com, a New York-based fund reported 319,868 shares. Royal Bank & Trust Of Canada has invested 0% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). 1,860 are held by National Bank Of America Corporation De. Two Sigma Secs Llc, a New York-based fund reported 11,603 shares. Northern Tru has 0% invested in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Agran Libbie reported 0.01% in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). Citigroup has 4,088 shares for 0% of their portfolio. Goldman Sachs Group reported 42,979 shares. Vanguard Group, a Pennsylvania-based fund reported 2.99 million shares. Moreover, D E Shaw & has 0% invested in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX). National Bank Of Mellon stated it has 66,772 shares.